Published in Nat Med on January 16, 2005
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30
Phosphoinositides: tiny lipids with giant impact on cell regulation. Physiol Rev (2013) 3.21
Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer (2010) 2.35
MicroRNA-184 antagonizes microRNA-205 to maintain SHIP2 levels in epithelia. Proc Natl Acad Sci U S A (2008) 2.25
Pten (phosphatase and tensin homologue gene) haploinsufficiency promotes insulin hypersensitivity. Diabetologia (2006) 1.72
Mice with a disruption of the imprinted Grb10 gene exhibit altered body composition, glucose homeostasis, and insulin signaling during postnatal life. Mol Cell Biol (2007) 1.63
Whole-genome analysis reveals that mutations in inositol polyphosphate phosphatase-like 1 cause opsismodysplasia. Am J Hum Genet (2012) 1.46
Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol (2014) 1.38
Exome sequencing identifies INPPL1 mutations as a cause of opsismodysplasia. Am J Hum Genet (2012) 1.36
MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. J Transl Med (2011) 1.22
Inositol 5-phosphatases: insights from the Lowe syndrome protein OCRL. Trends Biochem Sci (2012) 1.14
Rapid signaling at the plasma membrane by a nuclear receptor for thyroid hormone. Proc Natl Acad Sci U S A (2006) 1.08
Survival of monocytes and macrophages and their role in health and disease. Front Biosci (Landmark Ed) (2009) 1.06
The role of oxidative stress in the pathogenesis of type 2 diabetes: from molecular mechanism to clinical implication. Am J Transl Res (2010) 1.03
Phosphoinositide phosphatases in a network of signalling reactions. Pflugers Arch (2007) 1.03
Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2. Br J Pharmacol (2009) 1.02
Inpp5f is a polyphosphoinositide phosphatase that regulates cardiac hypertrophic responsiveness. Circ Res (2009) 1.00
The roles of ATF3, an adaptive-response gene, in high-fat-diet-induced diabetes and pancreatic beta-cell dysfunction. Mol Endocrinol (2010) 0.99
NMR studies of a heterotypic Sam-Sam domain association: the interaction between the lipid phosphatase Ship2 and the EphA2 receptor. Biochemistry (2008) 0.98
Frontier of epilepsy research - mTOR signaling pathway. Exp Mol Med (2011) 0.95
The inositol polyphosphate 5-phosphatase, PIPP, Is a novel regulator of phosphoinositide 3-kinase-dependent neurite elongation. Mol Biol Cell (2005) 0.94
Discovery and development of small molecule SHIP phosphatase modulators. Med Res Rev (2013) 0.91
Increased insulin action in SKIP heterozygous knockout mice. Mol Cell Biol (2008) 0.91
The control of phosphatidylinositol 3,4-bisphosphate concentrations by activation of the Src homology 2 domain containing inositol polyphosphate 5-phosphatase 2, SHIP2. Biochem J (2007) 0.90
Insulin signaling pathways and cardiac growth. J Mol Cell Cardiol (2008) 0.89
A screen for novel phosphoinositide 3-kinase effector proteins. Mol Cell Proteomics (2011) 0.88
Identification of genes that regulate multiple cellular processes/responses in the context of lipotoxicity to hepatoma cells. BMC Genomics (2007) 0.88
The inositol phosphatase SHIP-2 down-regulates FcgammaR-mediated phagocytosis in murine macrophages independently of SHIP-1. Blood (2005) 0.87
Role of TAPP1 and TAPP2 adaptor binding to PtdIns(3,4)P2 in regulating insulin sensitivity defined by knock-in analysis. Biochem J (2011) 0.86
Evidence for SH2 domain-containing 5'-inositol phosphatase-2 (SHIP2) contributing to a lymphatic dysfunction. PLoS One (2014) 0.84
The host phosphoinositide 5-phosphatase SHIP2 regulates dissemination of vaccinia virus. J Virol (2011) 0.84
A mutation in synaptojanin 2 causes progressive hearing loss in the ENU-mutagenised mouse strain Mozart. PLoS One (2011) 0.83
Opsismodysplasia resulting from an insertion mutation in the SH2 domain, which destabilizes INPPL1. Am J Med Genet A (2014) 0.83
SHIP2 (SH2 domain-containing inositol phosphatase 2) SH2 domain negatively controls SHIP2 monoubiquitination in response to epidermal growth factor. J Biol Chem (2009) 0.82
A second locus for schneckenbecken dysplasia identified by a mutation in the gene encoding inositol polyphosphate phosphatase-like 1 (INPPL1). Am J Med Genet A (2015) 0.82
SHIP2, a factor associated with diet-induced obesity and insulin sensitivity, attenuates FGF signaling in vivo. Dis Model Mech (2010) 0.82
Staying in SHIP shape. Nat Med (2005) 0.81
SHIP2 regulates epithelial cell polarity through its lipid product, which binds to Dlg1, a pathway subverted by hepatitis C virus core protein. Mol Biol Cell (2013) 0.81
LyGDI, a novel SHIP-interacting protein, is a negative regulator of FcγR-mediated phagocytosis. PLoS One (2011) 0.81
Genetic association analysis of inositol polyphosphate phosphatase-like 1 (INPPL1, SHIP2) variants with essential hypertension. J Med Genet (2007) 0.79
Genome-wide DNA Methylation Profiles of Small Intestine and Liver in Fast-growing and Slow-growing Weaning Piglets. Asian-Australas J Anim Sci (2014) 0.79
Phosphoinositides: Key modulators of energy metabolism. Biochim Biophys Acta (2014) 0.79
Regulation of insulin signaling by the phosphatidylinositol 3,4,5-triphosphate phosphatase SKIP through the scaffolding function of Pak1. Mol Cell Biol (2012) 0.79
Phosphoinositide 5-phosphatases: How do they affect tumourigenesis? J Biochem (2012) 0.79
PREP1 deficiency downregulates hepatic lipogenesis and attenuates steatohepatitis in mice. Diabetologia (2013) 0.78
The inositol Inpp5k 5-phosphatase affects osmoregulation through the vasopressin-aquaporin 2 pathway in the collecting system. Pflugers Arch (2011) 0.78
Variants of insulin-signaling inhibitor genes in type 2 diabetes and related metabolic abnormalities. Int J Genomics (2013) 0.77
Nanoscale Landscape of Phosphoinositides Revealed by Specific Pleckstrin Homology (PH) Domains Using Single-molecule Superresolution Imaging in the Plasma Membrane. J Biol Chem (2015) 0.77
Dynamics of mRNA and polysomal abundance in early 3T3-L1 adipogenesis. BMC Genomics (2014) 0.77
SHIPing news: a new way to keep your weight down. Cell Metab (2005) 0.76
FcγRIIb-SHIP2 axis links Aβ to tau pathology by disrupting phosphoinositide metabolism in Alzheimer's disease model. Elife (2016) 0.75
miR-184 exhibits angiostatic properties via regulation of Akt and VEGF signaling pathways. FASEB J (2016) 0.75
PI3K/SHIP2/PTEN pathway in cell polarity and hepatitis C virus pathogenesis. World J Hepatol (2017) 0.75
Insights into structure and function of SHIP2-SH2: homology modeling, docking, and molecular dynamics study. J Chem Biol (2011) 0.75
INPPL1 gene mutations in opsismodysplasia. J Hum Genet (2016) 0.75
Biofluid lipidome: a source for potential diagnostic biomarkers. Clin Transl Med (2017) 0.75
SHIP2 on pI3K/Akt pathway in palmitic acid stimulated islet β cell. Int J Clin Exp Med (2015) 0.75
Insulin signalling and glucose transport in the ovary and ovarian function during the ovarian cycle. Biochem J (2016) 0.75
Structural basis for interdomain communication in SHIP2 providing high phosphatase activity. Elife (2017) 0.75
Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell (2006) 8.48
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology (2012) 8.29
Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med (2012) 8.24
VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A (2002) 8.10
The knockout mouse project. Nat Genet (2004) 7.80
The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell (2004) 7.60
High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. Nat Biotechnol (2003) 7.47
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature (2006) 7.01
SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell (2006) 6.79
Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell (2002) 6.41
IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell (2004) 6.25
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest (2008) 5.96
Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity (2007) 5.73
VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest (2004) 5.59
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol (2005) 5.56
Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med (2013) 5.29
Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity (2008) 4.67
Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol (2004) 4.47
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis (2012) 4.42
Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci U S A (2004) 4.06
Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum (2008) 3.36
Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med (2002) 3.36
Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab (2012) 3.29
Lhx6 delineates a pathway mediating innate reproductive behaviors from the amygdala to the hypothalamus. Neuron (2005) 3.21
Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol (2009) 3.18
RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology (2008) 3.13
F0 generation mice fully derived from gene-targeted embryonic stem cells allowing immediate phenotypic analyses. Nat Biotechnol (2006) 3.13
During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J Cell Biol (2009) 3.03
Generation of functional multipotent adult stem cells from GPR125+ germline progenitors. Nature (2007) 3.01
The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer (2007) 2.96
The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab (2007) 2.84
Agouti-related protein-deficient mice display an age-related lean phenotype. Cell Metab (2005) 2.75
Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. Nat Med (2010) 2.75
Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol (2006) 2.74
VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med (2006) 2.67
Multiple knockout mouse models reveal lincRNAs are required for life and brain development. Elife (2013) 2.66
Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. Mol Cell Biol (2004) 2.58
Absence of ghrelin protects against early-onset obesity. J Clin Invest (2005) 2.53
Alternatively activated macrophage-derived RELM-{alpha} is a negative regulator of type 2 inflammation in the lung. J Exp Med (2009) 2.51
Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain. Nat Immunol (2007) 2.50
Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A (2002) 2.45
IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature (2012) 2.36
Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). Genes Dev (2004) 2.32
Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem (2004) 2.32
Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci (2004) 2.27
Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J Clin Invest (2002) 2.26
Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins. J Clin Invest (2007) 2.25
Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc Natl Acad Sci U S A (2004) 2.23
Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol (2002) 2.20
VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A (2007) 2.19
Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice. Proc Natl Acad Sci U S A (2010) 2.06
Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res (2003) 2.06
Muscle ring finger 1, but not muscle ring finger 2, regulates cardiac hypertrophy in vivo. Circ Res (2007) 2.05
Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc Natl Acad Sci U S A (2006) 2.03
Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood (2003) 2.03
Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J Clin Invest (2002) 1.95
Simultaneous deletion of ghrelin and its receptor increases motor activity and energy expenditure. Am J Physiol Gastrointest Liver Physiol (2007) 1.83
Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A (2003) 1.82
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med (2014) 1.82
Resistin-like molecule beta regulates innate colonic function: barrier integrity and inflammation susceptibility. J Allergy Clin Immunol (2006) 1.79
Endogenous muscle atrophy F-box mediates pressure overload-induced cardiac hypertrophy through regulation of nuclear factor-kappaB. Circ Res (2011) 1.79
Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2012) 1.78
Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J Invest Dermatol (2006) 1.72
VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol (2003) 1.71
Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3. J Clin Invest (2007) 1.70
Angiopoietin-1 therapy enhances fibrosis and inflammation following folic acid-induced acute renal injury. Kidney Int (2008) 1.70
Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol (2002) 1.68
Loss-of-function analysis of EphA receptors in retinotectal mapping. J Neurosci (2004) 1.67
Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol (2003) 1.63
The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J Cell Biol (2010) 1.61
Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res (2007) 1.60
Electrical impedance as a novel biomarker of myotube atrophy and hypertrophy. J Biomol Screen (2011) 1.59
EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells. FASEB J (2002) 1.58
VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys (2007) 1.55
Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) (2012) 1.53
Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung. Proc Natl Acad Sci U S A (2011) 1.51
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. Circ Cardiovasc Genet (2015) 1.50
Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res (2012) 1.50
VEGF blockade inhibits angiogenesis and reepithelialization of endometrium. FASEB J (2008) 1.48
Protective effects of angiopoietin-like 4 on cerebrovascular and functional damages in ischaemic stroke. Eur Heart J (2013) 1.47
TLR8 deficiency leads to autoimmunity in mice. J Clin Invest (2010) 1.46
Vascular endothelial growth factor regulates reendothelialization and neointima formation in a mouse model of arterial injury. Circulation (2004) 1.45